<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Oruka Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/oruka-therapeutics-inc</link>
<description>Latest news and press releases for Oruka Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 23:42:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/oruka-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a72078dffbe2df10bcce.webp</url>
<title>Oruka Therapeutics, Inc.</title>
<link>https://6ix.com/company/oruka-therapeutics-inc</link>
</image>
<item>
<title>Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-pricing-of-upsized-dollar700-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-pricing-of-upsized-dollar700-million-underwritten-public-offering</guid>
<pubDate>Tue, 28 Apr 2026 23:42:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced the pricing of its upsized underwritten public offering of 9,660,000 shares of its common stock at a price to the public of $72.50 per share. The gross proceeds to Oruka from this offering are expected to be approximate</description>
</item>
<item>
<title>Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-proposed-dollar500-million-underwritten-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-proposed-dollar500-million-underwritten-public-offering</guid>
<pubDate>Mon, 27 Apr 2026 20:17:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications, today announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addit</description>
</item>
<item>
<title>Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-week-16-data-for-orka-001-from-the-ongoing-everlast-a-phase-2a-trial-in-moderate-to-severe-plaque-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-week-16-data-for-orka-001-from-the-ongoing-everlast-a-phase-2a-trial-in-moderate-to-severe-plaque-psoriasis</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 Favorable safety profile consistent with the IL-23p19 class Updated Phase 1 PK/PD data continue to support the potential for once-yearly dosing, with longer-term EVERLAST-A data expected in 2H 2026 Management to host a conference call today at 8:00 a.m. ET MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a n</description>
</item>
<item>
<title>Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-a-trial-on-april-27-2026</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-a-trial-on-april-27-2026</guid>
<pubDate>Sun, 26 Apr 2026 16:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on Monday, April 27, 2026. Following the announcement, the company will host a conference call and webcast at 8:00</description>
</item>
<item>
<title>Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the t</description>
</item>
<item>
<title>Oruka Therapeutics to Participate in Multiple Upcoming Conferences</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-participate-multiple-upcoming-conferences-2026-02-09</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-participate-multiple-upcoming-conferences-2026-02-09</guid>
<pubDate>Mon, 09 Feb 2026 05:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-data-orka-002-and-initiation</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-data-orka-002-and-initiation</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in</description>
</item>
<item>
<title>Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-44th-annual-120000551</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-44th-annual-120000551</guid>
<pubDate>Tue, 06 Jan 2026 12:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing...</description>
</item>
<item>
<title>Oruka Therapeutics Announces New Board Member and Board Transition</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-new-board-member-and-board-transition-2025-12-11</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-new-board-member-and-board-transition-2025-12-11</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>Appoints accomplished commercial leader Chris Martin to its Board of Directors MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc.</description>
</item>
<item>
<title>Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and</description>
</item>
<item>
<title>Oruka Therapeutics to Present at Multiple November Investor Conferences</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-multiple-november-investor-conferences-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-multiple-november-investor-conferences-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces $180 Million Private Placement</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-180-million-private-placement-2025-09-17</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-180-million-private-placement-2025-09-17</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-results-orka-001-2025-09-17</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-positive-interim-phase-1-results-orka-001-2025-09-17</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could</description>
</item>
<item>
<title>Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Mon, 11 Aug 2025 04:00:00 GMT</pubDate>
<description>First patients dosed in the EVERLAST-A Phase 2a trial of ORKA-001, with data expected in 2H 2026 ORKA-001 Phase 1 data and EVERLAST-A design to be presented</description>
</item>
<item>
<title>Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-ind-clearance-everlast-phase-2a-trial-orka-001-psoriasis</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-ind-clearance-everlast-phase-2a-trial-orka-001-psoriasis</guid>
<pubDate>Mon, 21 Jul 2025 04:00:00 GMT</pubDate>
<description>IND cleared for the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe psoriasis, with initial data expected 2H 2026 Interim Phase 1 data and further</description>
</item>
<item>
<title>Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-promotion-laura-sandler-chief-operating-officer-2025-07</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-promotion-laura-sandler-chief-operating-officer-2025-07</guid>
<pubDate>Tue, 01 Jul 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-jefferies-global-healthcare-conference-2025-05-21</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-jefferies-global-healthcare-conference-2025-05-21</guid>
<pubDate>Wed, 21 May 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing</description>
</item>
<item>
<title>Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-first-participants-dosed-phase-1-trial-orka-002-its</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-announces-first-participants-dosed-phase-1-trial-orka-002-its</guid>
<pubDate>Tue, 20 May 2025 04:00:00 GMT</pubDate>
<description>Pharmacokinetic and safety data from healthy volunteers anticipated around YE 2025 On track to initiate a Phase 2 study in 1H 2026 ORKA-002 preclinical data</description>
</item>
<item>
<title>Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-first-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-reports-first-quarter-2025-financial-results-and-provides</guid>
<pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
<description>Continued operational excellence leading to acceleration of multiple timelines: ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data</description>
</item>
<item>
<title>Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference</title>
<link>https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-bank-america-securities-2025-health-care-conference-2025</link>
<guid isPermaLink="true">https://6ix.com/company/oruka-therapeutics-inc/news/oruka-therapeutics-present-bank-america-securities-2025-health-care-conference-2025</guid>
<pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing</description>
</item>
</channel>
</rss>